Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价康龙胶囊治疗晚期原发性肝癌有效性和安全性的随机、双盲、安慰剂对照的二期临床试验
[Translation] A randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of Kanglong capsule in the treatment of advanced primary liver cancer
1、初步评价康龙胶囊治疗晚期原发性肝癌(瘀毒内结证)有效性; 2、初步评价康龙胶囊治疗晚期原发性肝癌(瘀毒内结证)安全性; 3、探索康龙胶囊治疗晚期原发性肝癌最佳的给药剂量。
[Translation] 1. To preliminarily evaluate the effectiveness of Kanglong Capsules in treating advanced primary liver cancer (with stasis and toxic accumulation syndrome); 2. To preliminarily evaluate the safety of Kanglong Capsules in treating advanced primary liver cancer (with stasis and toxic accumulation syndrome); 3. To explore the optimal dosage of Kanglong Capsules in treating advanced primary liver cancer.
100 Clinical Results associated with Dongya Cancer Institute, Changsha City, Hunan Province
0 Patents (Medical) associated with Dongya Cancer Institute, Changsha City, Hunan Province
100 Deals associated with Dongya Cancer Institute, Changsha City, Hunan Province
100 Translational Medicine associated with Dongya Cancer Institute, Changsha City, Hunan Province